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Abstract: Many biological properties of algae have been found to have useful applications 
in human health, particularly in the fields of oncology and immunology. Floridoside, 
extracted from the red alga Mastocarpus stellatus, has a structure similar to the 
xenoantigen Gal alpha 1-3 Gal. This xenoantigen has been described to induce a high 
immune response in human xenografts and is mediated by natural anti-gal antibodies that 
activate the classical complement pathway. Based on this property, we analyzed the 
potential activities of floridoside on the immune system. We demonstrated that floridoside 
activates a complement cascade via the classical complement pathway, through the 
recruitment and activation of natural IgM. This algal molecule could represent an 
important step in the development of a potent new anticomplementary
 agent for use in 
therapeutic complement
 depletion.  
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1. Introduction  
 
Molecules isolated from marine organisms have already been reported to possess antitumoral 
activities. However, in comparison to sponges, mollusks or ascidians, algae have been at the origin of 
only few studies focused on oncological or immunological applications. In fact, biological properties of 
oncological or immunological interest have been demonstrated in 140 species of algae, but molecules 
from only three species of red algae are currently in preclinical trials. Previous studies have often been 
limited to preliminary screening without collaboration with pharmaceutical laboratories for developing 
new drugs. Nevertheless, the discovery, isolation and characterization of new bioactive marine 
molecules (especially terpenes, polysaccharides, alkaloids, halogenated compounds, phenolic 
compounds, etc.) from different types of marine algae should generate many productive studies in terms 
of potentially useful biological properties in the near future. 
Floridoside is a neutral heteroside found in many red algae originally isolated from the 
Rhodophyceae Rhodymenia palmate or Mastocarpus stellatus. Produced directly from photosynthesis, 
floridoside constitutes an important soluble carbon reserve readily available according to cellular 
needs [1,2] and, in aqueous solution, it behaves as an osmoregulator involved in the resistance of the 
algal cell wall to changes in external salinity. The molecular structure of floridosides was first 
established by Putman and Hassid [3] in 1954, who characterized it as a 2-O-α-D-
galactopyranosylglycerol. The terminal Galα(1-3) structure of this molecule is similar to the linear B 
trisaccharide (Galα(1-3)Galβ(1-4)GlcNAc) named Gal xenoantigen or Galili epitope [4]. This antigen 
is responsible for the human xenograft rejection due to the presence of natural anti-gal antibodies. 
These antibodies are mainly immunoglobulins of type M and G (IgM and IgG) with a strong capacity 
to activate the classical complement pathway, through recruitment and activation of the C1q protein 
that ultimately leads, to cell destruction by forming the membrane attack complex (MAC).  
Because of the structural similarity between floridoside and Galili epitope, we were interested in 
evaluating the activity of the floridoside on the complement system. First, floridoside was extracted 
from the red alga Mastocarpus stellatus, purified and characterized. Then, its  activity on the 
complement system was tested using hemolytic assays as well as in a solid-phase Enzyme-Linked 
Immunosorbent Assay (ELISA) system and, finally, compared to Galili epitope activity. The results 
obtained with floridoside are presented here and the potential biological applications of this molecule 
are discussed. 
 
2. Results and Discussion  
2.1. Extraction, purification and chemical structure 
 
The floridoside was extracted from the red alga Mastocarpus stellatus with a mixture of MeOH-
CHCl3-H2O and was purified from the hydroalcoholic fraction. The chemical structure was determined 
as C9H18O8 (with a molecular weight of 253 g.mol
-1) on the basis of NMR and GC/MS analysis. This 
structure was in complete agreement with those published by Simon-Colin et al. [1,2]. Based on these 
data, floridoside was confirmed as ((2-O- α-D-galactopyranosyl)1→2’ (glycerol)) (Figure1). 
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Figure 1. Chemical structure of floridoside. 
O
OH
O
O H
HO
OH
OH
OH 
2.2. Biological activities of floridoside 
 
The complement system is a major effector of humoral immunity involved in host defense. It is a 
complex system comprised of at least 30 serum proteins, such as C4 or C2 molecules, which interact in 
a cascade of activation. Many of the early components are serine proteases, which activate each other 
sequentially. The activation cascade results in the formation of MAC that perforates the plasma 
membrane of the target cell [5,6]. In order to determine the role of floridoside on the complement 
system, hemolytic assays were analyzed after contact with sensitized sheep erythrocytes.  
The effect of different floridoside concentrations was determined in vitro using normal human 
serum (NHS) as the complement source. As a first approach, we validated the experimental model by 
testing different concentrations of aggregated IgG. Aggregated IgG is known to be a powerful 
activator of the complement system and was used as a positive control for the reaction [7]. The 
capacity of the NHS serum to restore the hemolytic activity of a serum deficient in one protein of the 
complement system was measured. First, the CH50 representing the NHS dilution that leads to 50% 
lysis was determined. In our experiments, CH50 was reached at a 1:100 dilution. Then, increasing 
amounts of aggregated IgG (0-100 µg) in CH50 NHS conditions were incubated with a C2-deficient 
serum and the complement activation was determined by measuring the amount of released 
hemoglobin. The rate of activation by aggregated IgG in veronal buffer (VBS
2+) increased very rapidly 
with amounts of IgG and reached a plateau corresponding to 80% (data not shown). These results 
confirm that aggregated IgG is a very efficient activator. The same experimental conditions were 
applied to floridoside. Increasing amounts of floridoside (0-100 µg) in CH50 NHS conditions were 
incubated with a C4-deficient or C2-deficient serum and complement activation was determined by 
measuring the amount of released hemoglobin. As shown in Figure 2A, the rate of activation by 
floridoside in veronal buffer (VBS
2+) increased very rapidly with amounts of floridoside and reached a 
plateau corresponding to 100%. These results indicate that floridoside was very efficient in activating 
the complement system, with a rate of 50% (AC 50) at 1.5 µg and 2 µg using C2- and C4-deficient 
serum, respectively (Figure 2B).  
Complement activation can be initiated by three pathways, all of them generating homologous 
variants of the protease C3-convertase. Typically, the classical complement pathway requires 
antibodies for activation (specific immune response), while the alternative and the mannose-binding 
lectin (MBL) pathways can be activated either by C3 hydrolysis or by antigens and does not require 
the presence of antibodies (non-specific immune response) (Figure 3). The C4 and C2 proteins used in 
our test conditions are specific to both classical and MBL pathways. In order to identify which Mar. Drugs 2008, 6                                                 
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particular pathway of the complement system was activated by floridoside, additional assays were 
carried out using a human C1q-deficient serum specific to the classical pathway along with varying 
amounts of floridoside (10, 50 and 100 µg). The results, presented in the Figure 4, demonstrated that 
activation occurred using the C1q-deficient serum, indicating that floridoside was specifically involved 
in the classical pathway.  
Figure 2. Floridoside activation of the complement system. Activation was measured by 
the capacity of NHS incubated with various quantities of floridoside to restore serum 
deficient or depleted in complement proteins C4 and C2, respectively. (A) Activation using 
a wide range of floridoside concentrations. (B) Close-up of (A) for floridoside quantities 
≤ 10 µg. Each point represents the mean (± SE) determined from three to six trials. 
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In order to confirm that the classical pathway was specifically activated by floridoside, the 
production of C4d protein was measured by ELISA assays. Classical pathway activation is triggered 
upon the binding of the C1q component to IgG- or IgM-containing immune complexes or other 
activating molecules. The binding of C1q to one of these activators results in the conversion of the C1 
complex to an active proteolytic enzyme cleaving C4 to C4a and C4b. As an anaphylatoxin, C4a has a 
short half-life and is bound by cells possessing the appropriate receptors. C4b mediates opsonization of 
target cells and can participate in the formation of the classical pathway C3-convertase. C4b is rapidly 
cleaved by factor I, generating the fragments C4c and C4d. In our experiment, NHS was incubated 
with various amounts of floridoside (5 µg, 50 µg and 100 µg) and the C4d produced by the 
complement activation was determined using the Quidel® C4d EIA Kit. Our results showed that 
floridoside induced the production of C4d in a dosage-dependent way, confirming that it activates the 
complement system through the classical pathway (Figure 5). Mar. Drugs 2008, 6                                                 
 
 
411
Figure 3. The three main pathways that activate the complement system. 
 
Figure 4. Quantity-response curves of floridoside activation of the complement system. 
Activation was measured by the capacity of NHS incubated with various quantities of 
floridoside on restoring serum deficient in complement proteins (C1q). Each point 
represents the mean (± SE) determined from three to six trials. 
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Figure 5. C4d production in NHS incubated with floridoside determined by ELISA assays. 
Each point represents the mean determined from four trials. 
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Moreover, the classical pathway can be activated via two main mechanisms: (1) a direct activation 
of the C1q protein or (2) the natural recruitment of IgM able to activate the system. In order to 
determine the mechanism of activation, we evaluated the activation of the complement system in a 
serum obtained from umbilical cord blood (US) in which IgM are lacking [8]. Various quantities of 
floridoside (5 µg, 10 µg and 50 µg) were incubated with US and the complement system activation 
was evaluated by hemolytic assays using human serum deficient in the C2 protein. Results were 
compared to those obtained using NHS (Figure 6). Floridoside activation using US was significantly 
weaker than the one measured using NHS under the same experimental conditions. This result 
indicates that activation of the classical complement pathway by floridoside is mediated by natural 
IgM. The observed residual activity was most likely due to natural IgG directed against floridoside. 
We can conclude that floridoside constitutes a potent activator of the classical complement pathway 
and this activation seems to be mediated by the recruitment and the activation of natural IgM directed 
against this molecule. Floridoside possesses an alpha-Gal terminal structure similar to the Galili 
epitope. As noted previously, this α-galactosyl core is absent in human cells but is naturally 
expressed—with millions of epitopes per cell—on glycolipids and glycoproteins in non-primate 
mammals, prosimians (e.g. lemurs) and New World monkeys (monkeys of South and Central America) 
[4, 9, 10]. This epitope is responsible for xenograft rejection, via the complement system, by recruiting 
and activating natural IgM and IgG [11]. Anti-Gal IgM and IgG molecules are the most abundant 
natural antibodies in humans, constituting about 1% of the total immunoglobulins present in serum [9, 
12, 13, 14]. Given the structural similarity of floridoside and this immunogenic epitope, we 
hypothesized that the activation of the complement system by floridoside could be due to these natural 
anti-Gal antibodies. We performed experiments to compare the capacity of these two molecules to 
activate the classical pathway. Hemolytic assays were thus carried out by measuring the restoration of 
a C4-deficient serum with NHS incubated by various amount of floridoside or Galili epitope (1, 2, 4, 
10, 20, 40 µmol). The results, presented in Figure 7, indicate that, unlike floridoside, the Galili epitope Mar. Drugs 2008, 6                                                 
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is not able to activate the complement system. This confirms that the floridoside molecule is able to 
activate the complement system through its recognition by natural IgM. Furthermore, the main 
condition for the initiation of complement activation by α-Gal epitope is its fixation to the cell surface. 
This hypothesis is confirmed by the use of this epitope alone in therapy and by its capacity to interact 
with natural immunoglobulins (IgM or IgG) without triggering an immune response [15]. A difference 
in epitope orientation and accessibility (free or linked) could explain why the Galili epitope in this 
assay did not induce the expected results [4, 9]. Using gas chromatography coupled with mass 
spectrometry, we verified that floridoside was not aggregated in solution since aggregates could have 
conferred the observed biological activity (data not shown). This study clearly demonstrated that 
activation of the complement system by floridoside is undoubtedly due to natural IgM directed against 
this molecule. However, we do not yet have direct evidence that these antibodies are natural anti-Galili 
epitope IgM. Additional studies are required to determine which type of IgM actually interacts with 
the floridoside and confers the capacity to activate the complement system. 
Figure 6. Evaluation of floridoside complement activation using NHS and umbilical serum 
(US). Experiments were performed using serum deficient in the C4 protein. Each point 
represents four trials analyzed using the Student’s t-test and ANOVA. The asterisk (*) 
represents significant differences (p<0.05) between NHS and US at a given quantity. 
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In summary, natural floridoside was purified from the red alga Mastocarpus stellatus and identified 
as a (2-O-α-D-galactopyranosyl)1→2’ (glycerol)). Biological results obtained in this study strongly 
indicate a close relationship between floridoside and innate immunity. This is the first time that the 
molecule of floridoside has been described as an activator of the complement system, particularly via 
the classical pathway. This activation is probably due to natural IgM and our results confirm that 
immune complexes are formed in solution with floridoside. Substantial efforts are being devoted to 
develop new drugs for complement
 inhibition [16]. However, these experimental drugs aim to inhibit
 
complement activation by rapidly consuming enzymatic cascade proteins or by depleting them [17]. 
Floridoside, as a new natural molecule, may represent a promising new anticomplementary
 agent. 
Furthermore, the complement system plays an important role in the immunotherapeutic action of Mar. Drugs 2008, 6                                                 
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monoclonal antibodies [18], particularly in the treatment of cancer. In combination with monoclonal 
antibodies, floridoside could be used to enhance the biological activity of new targeted therapies and 
may thereby be a potentially useful drug for cancer therapy.  
Figure 7. Comparison between floridoside and α-Gal epitope in their capacity to activate 
the complement system. This experiment was performed using serum deficient in the C4 
protein. Each point represents four trials analyzed using Student’s t-test and ANOVA. The 
asterisk (*) represents significant differences (p<0.05) between floridoside and α-Gal 
epitope at a given concentration. 
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3. Experimental 
3.1. Materials 
Normal Human Serum (NHS) and Umbilical Serum (US) were obtained from healthy donors 
(National Blood Transfusion Service, Brest, France). Human complement C1q- and C2-deficient sera 
were purchased from Calbiochem (La Jolla, CA, USA). Guinea pig complement C4-deficient serum 
was purchased from Quidel (San Diego, USA). Sheep erythrocytes were commercially available 
(Eurobio, Paris, France). Rabbit anti-sheep erythrocytes antibodies were purchased from Biomerieux 
(Paris, France). ELISA C4d quantification kit was purchased from Quidel Corporation (San Diego, 
USA). Trisaccharide Galα(1-3)Gal-β(1-4)GlcNAc was ordered from Carbohydrate Synthesis (Oxford, 
UK). IgG was purchased from Roche (Paris, France).  
3.2.Buffers 
The following buffers were used: Phosphate Buffered Saline (PBS) 10 mM, pH 7.4; Veronal Buffer 
Saline (VBS
2+): 4 mM veronal (Sigma-Aldrich, Saint-Quentin Fallavier, France), 0.15 mM NaCl 
(Sigma-Aldrich, Saint-Quentin Fallavier, France), 0.15 mM Ca
2+  (Sigma-Aldrich, Saint-Quentin Mar. Drugs 2008, 6                                                 
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Fallavier, France), 0.5 mM Mg
2+ (Sigma-Aldrich, Saint-Quentin Fallavier, France), pH 7.3. Tris HCl 
Buffer 10 mM, pH 7.5. Citrate Buffer 0.1 M, pH 3.0.  
3.3. Extraction and isolation of floridoside 
Mastocarpus stellatus (Stackhouse) Guiry was harvested from the mid-sublittoral zone at Plouzané, 
in the Bay of Brest, France. Fresh material was washed with distilled water and frozen in liquid 
nitrogen. [Frozen] plant material (200 g) was ground in liquid nitrogen and then extracted with a 
mixture of 12:5:3 MeOH-CHCl3-H2O (400 mL) for 1 h at room temperature. The hydroalcoholic phase 
was concentrated in a rotary evaporator, and then purified by passing it through successive columns of 
AG50 (200 mL, 20-50 mesh, X8, H
+, Biorad) and AG1 (200 mL, 20-50 mesh, X8, OH
-, Biorad). The 
neutral effluent was evaporated to dryness and redissolved in hot EtOH. White crystals of floridoside 
(500 mg) were obtained after partial evaporation of the alcoholic fraction. 
3.4. Capacity of normal human serum to lyse 50% of sensitized erythrocytes through the classical 
pathway (CH50 assay)  
Antibody-sensitized sheep erythrocytes (AE) were prepared by incubating sheep erythrocytes with 
rabbit anti-sheep erythrocytes antibodies (Biomerieux, Paris, France) as described by Kazatchkine 
[19]. 
The CH50 represents the NHS concentration that leads to 50% AE lysis. To determine CH50, different 
concentrations of NHS (800 µL), in VBS
2+, were incubated with 200 µL of AE at 10
8 cells.mL
-1 for 45 
min at 37°C. The controls corresponding to 0% (L0) and 100% (L100) lysis were obtained by incubation 
in the same conditions with 800 µL of VBS
2+ and 200 µL of AE. After dilution in cold 0.15 M NaCl (2 
mL) solution (except the one corresponding to the L100, where 2 mL of double distilled water (DDW) 
were added) and centrifugation, the residual CH50 units of the supernatants, corresponding to lysed EA 
hemoglobin, were determined by measuring the optical density (OD) at 414 nm (Uvikon, Serlabo, 
Bonneuil/Marne, France) [20]. 
3.5. Hemolytic assay for evaluation of the classical complement pathway activation  
For the evaluation of the capacity of the floridoside to activate the complement system, various 
amounts of floridoside (0 to 100 µg) were pre-incubated with 15 µL of NHS (1/20 in VBS
2+) for 45 
min at 37°C. Then, a mixture of 100 µL of deficient serum in C1q, C2 or C4 proteins (whose dilution 
factor was previously determined to obtain 90% cell lysis in these experimental conditions) and 100 
µL of AE at 10
8 cells.mL
-1 were added and incubated for another 45 min at 37°C. The controls L0 and 
L100 were obtained as previously described. After dilution with cold 0.15 M NaCl (2 mL) and 
centrifugation, the amount of the supernatant hemoglobin released was assessed by measuring OD at 
414 nm. A positive control for the reaction was obtained by incubation of aggregated IgG in the same 
experimental conditions [7]. For the comparison of the floridoside and the trisaccharide Galα(1-
3)Galβ(1-4)GlcNAc activity, various concentrations of each molecule (0-40 µmol) were treated under 
the same experimental conditions. Mar. Drugs 2008, 6                                                 
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3.6. ELISA for the detection of complement activation products: Quantification of the C4d protein 
In order to evaluate complement activation by ELISA assays, the C4d protein production was 
measured. Briefly, various quantities of floridoside or aggregated IgG (0-100 µg) were incubated with 
NHS (1/25 in VBS
2+) for 45 min at 37°C. The amount of C4d was quantified using the commercial kit 
from Quidel (San Diego, USA), which was used according to the manufacturer’s instructions. 
3.7. Statistical analysis  
All results are expressed as means ± standard error. Statistical differences between experimental 
groups were determined by ANOVA and individual means were compared with Student’s t-test using 
InStat (GraphPad Software, San Diego, CA, USA). Values of p < 0.05 were considered statistically 
significant. 
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